Journal of Jilin University Medicine Edition ›› 2013, Vol. 39 ›› Issue (3): 534-538.doi: 10.7694/jldxyxb20130323

Previous Articles     Next Articles

Targeted inhibition  of  hTERTp/TK/pGL3  on telomerase activity  and its killing effect on nasopharyngeal  cancer stem cells

YANG Ke-ke,SHEN Cong-xiang,WEN Zhong,GUAN Xiao-fang,LAI Xiao-fen,QIAN Yu-hong   

  1. Department of Otorhinolaryngology and Head-Neck Surgery,Zhujiang Hospital,Nanfang Medical University,Guangzhou 510282,China
  • Received:2012-01-18 Online:2013-05-28 Published:2013-07-01

Abstract: Abstract:Objective To explore the mechanism of  targeted inhibition of hTERTp/TK/pGL3 vector on  the telomerase activity and its killing effect on nasopharyngeal cancer stem cells.Methods The nasopharyngeal carcinaoma CD133+ stem cells,CD133-tumor cells, human umbilical vein endothelial cells (ECV cells) (control group) and nasopharyngeal carcinaoma SUNE unsorted cells were transfected by hTERTp/TK/pGL3 vector and its control vectors (CMV/TK/pGL3 and TK/pGL3).The telomerase avtivities of nasopharyngeal carcinaoma CD133+ stem cells and ECV cells were detected by Stretch PCR.The survival rates of CD133+stem cells and ECV cells were detected by  MTT method.Results After culture for 7 d in vitro,the number of nasopharyngeal carcinaoma CD133+ stem cells was increased, the tumorigenicity test of CD133+ stem cells  in vivo was positive.The telomerase activity of nasopharyngeal carcinaoma CD133+ stem cells was decreased after transfected by hTERTp/TK/pGL3 or CMV/TK/pGL3; the telomerase activity of EVC cells was negative.After transfected by TK/pGL3,CMV/TK/pGL3,and hTERTp/TK/pGL3,the  survival rates of CD133+ stem cells were 87.4%±0.4%,20.5%±0.4%,and 27.9%±0.2%,respectively. After transfected by TK/pGL3,CMV/TK/pGL3,and hTERTp/TK/pGL3,the  survival rates of ECV cells were 90.7%±0.1%,18.1%±0.2%,and 86.2%±0.1%,respectively.The efficiency of  hTERTp/TK/pGL3 vector  in  killing CD133+ stem cells was higher than that of  ECV cells(P<0.01).Conclusion hTERTp/TK/pGL3 vector can targetedly inhibit the telomerase-positive nasopharyngeal carcinaoma CD133+ stem cells by down-regulation of telomerase activity.

Key words: nasopharyngeal neoplasms, CD133+tumor stem cells, targeted tumor therapy, telomerase

CLC Number: 

  • R73-3